We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » POSTMARKETING GUIDANCE POINTS TO OBSERVATIONAL DATA
POSTMARKETING GUIDANCE POINTS TO OBSERVATIONAL DATA
May 7, 2004
After a drug has entered the marketplace, it is critical for manufacturers to collect safety data and assess risk based on observational data in order to evaluate and characterize a product's risk profile and to make informed decisions to minimize those risks, the FDA said in a draft guidance released last week.